Kezar Life Sciences, Inc. (KZR) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 2 Buy, 5 Hold.
The consensus price target is $6.00 (low: $5.00, high: $7.00), representing a downside of 18.5% from the current price $7.36.
Analysts estimate Earnings Per Share (EPS) of $-5.77 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.15 vs est $-5.77 (beat +80.1%). 2025: actual $-7.66 vs est $-6.70 (missed -14.2%). Analyst accuracy: 0%.
KZR Stock — 12-Month Price Forecast
$6.00
▼ -18.48% Downside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Kezar Life Sciences, Inc., the average price target is $6.00, with a high forecast of $7.00, and a low forecast of $5.00.
The average price target represents a -18.48% change from the last price of $7.36.
Highest Price Target
$7.00
Average Price Target
$6.00
Lowest Price Target
$5.00
KZR Analyst Ratings
Hold
Based on 7 analysts giving stock ratings to Kezar Life Sciences, Inc. in the past 3 months
EPS Estimates — KZR
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.15
vs Est –$5.77
▲ 401.3% off
2025
Actual –$7.66
vs Est –$6.70
▼ 12.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — KZR
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
